Evidence map›Paper›PMID 41863683›Full record

ReviewJournal of clinical immunology2026

Fostamatinib Dual Immunomodulation in Post-Haploidentical HSCT Autoimmune Cytopenia and Autoimmune Hepatitis: A Case Report and Review of Literature.

Antimo Tessitore, Debora Curci, Aurelio Sonzogni, Martina Franzin, Giulia Schillani, Anna Flamigni, Gilda Paternuosto, Natalia Maximova

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Antimo TessitoreDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Debora CurciLaboratory of Advanced Translational Diagnostics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Aurelio SonzogniDepartment of Pathology, ASST Bergamo Est, Bergamo, Italy.
Martina FranzinLaboratory of Advanced Translational Diagnostics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Giulia SchillaniDepartment of Pediatrics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Anna FlamigniPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Gilda PaternuostoPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Natalia MaximovaDepartment of Pediatrics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy. natalia.maximova@burlo.trieste.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the effectiveness and safety of fostamatinib off-label use in a pediatric patient with autoimmune cytopenia and autoimmune hepatitis following allogeneic hematopoietic stem cell transplantation (HSCT).

methodsWe report the detailed changes in clinical, histopathological, and cytokine profiling in a pediatric HSCT recipient during treatment with fostamatinib.

resultsFostamatinib administration was well-tolerated with no adverse events observed, leading to sustained hematological recovery and a significant improvement in liver enzyme levels. Histological features confirmed the complete remission of autoimmune hepatitis. Cytokine profiling demonstrated substantial normalization of pro-inflammatory markers, downregulated at onset.

conclusionFostamatinib demonstrated a dual benefit in resolving autoimmune cytopenia and immune-mediated liver inflammation, supporting its potential as a therapeutic option for immune dysregulation following allogeneic HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationHepatitis, AutoimmuneOxazinesPyridinesAminopyridinesCytokinesCytopeniaFemaleHumansImmunomodulationMaleMorpholinesPyrimidinesTransplantation, HomologousTreatment OutcomeAminopyridinesCytokinesfostamatinibMorpholinesOxazinesPyridinesPyrimidinesAutoimmune cytopeniaAutoimmune hepatitisFostamatinibPediatricPro-inflammatory cytokinesTCRαβ + depleted haploidentical hematopoietic stem cell transplant

Identifiers

PMID41863683
PMCPMC13053572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.